In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

European cardiomyopathies registry finds high use of defibrillators and genetic testing

London, UK – 1 Sept 2015: The most representative snapshot of real world practice in cardiomyopathies in Europe has shown a higher than expected use of defibrillators and genetic testing. The baseline results of the ESC’s EORP Cardiomyopathy Registry Pilot are presented for the first time today at ESC Congress 2015.1

Cardiomyopathies
Genomics
ICD and CRT


EMBARGO : 1 September 2015 at 14:30 BST

“This is the first time that we have a snapshot of practice in cardiomyopathies across different European countries with diverse healthcare systems,” said principal investigator Professor Perry Elliott, professor in inherited cardiovascular disease at The Heart Hospital and University College London, UK. “The literature is dominated by studies from a small number of large centres and none of the research has been so representative of Europe as a whole.”

Cardiomyopathies are a common group of conditions that occur in one out of 200 to 300 people in Europe. They are genetic, which makes diagnosis important not only for patients but also for their families. All cardiomyopathies are associated with premature death, predominantly from sudden cardiac death and progressive heart failure but also from stroke. None of the conditions are curable but there are clear strategies for reducing or eliminating complications so diagnosis is crucial.

The EORP Cardiomyopathy Registry Pilot2 is a prospective, multicentre, observational study of patients presenting to 27 referral cardiomyopathy centres in 12 European countries. In 2012 and 2013 investigators examined the characteristics of 1 115 patients with hypertrophic (HCM), dilated (DCM), arrhythmogenic right ventricular (ARVC) and restrictive (RCM) cardiomyopathy.

Participating centres were required to have dedicated cardiomyopathy clinics staffed by experienced medical and nursing teams and access to facilities for genetic testing with skills in interpreting the results. Each centre was asked to contribute up to 40 consecutive patients aged over 18 years during a 12 month period.

The commonest cardiomyopathy was HCM (61%) followed by DCM (31%), ARVC (5%) and RCM (3%). One of the most striking findings was that 316 patients (28.3%) had received an implantable cardioverter defibrillator (ICD). The proportion was highest in patients with ARVC (57.6%) and lowest in those with RCM (6.9%). The majority of ICDs were for primary prophylaxis. Some 8% of patients had a pacemaker alone and 5.2% had a cardiac resychronisation therapy (CRT) device.

“Nearly 60% of patients with ARVC had an ICD which is extremely high,” said Professor Elliott. “We don’t fully understand why that is yet. It may be because referral centres see the highest risk patients or therapy may be more aggressive in the real world than guidelines recommend, with a lower threshold for putting in a defibrillator than anticipated.”

Also striking was the finding that 462 patients (41.4%) had genetic testing, with a causative mutation reported in 236 (51.1%). “This is the first time that data has been collected on the scale of genetic testing in patients with cardiomyopathies,” said Professor Elliott. “The results show that the use of genetic testing is high and efficient, with more than half of the tests yielding a positive result.”

Nearly 60% of HCM and ARVC patients and 70% of DCM patients were men. Slightly more than half of RCM patients were women. Professor Elliott said: “Most of the diseases were more common in men which has been described before but is poorly understood. It could be that men have more severe disease or there may be systematic underdiagnosis in women.”

The registry showed that one third of patients with a cardiomyopathy were diagnosed either incidentally or through family screening. “Cardiologists, GPs and other physicians need to be alert to the fact that these are quite common conditions that can appear through different routes,” said Professor Elliott.

He concluded: “Patients with cardiomyopathies need intensive investigation using specialised diagnostic tests. Many of the findings reported today, including the very high use of ICDs in ARVC and the high yield from genetic testing, will be examined in substudies from the pilot and in the long-term registry which will also include non-referral centres, centres outside Europe, paediatric patients and, for the first time in a large international registry, myocarditis.”

ENDS

References

1Professor Elliott will give the lecture ‘Presentation of the main results of the pilot phase of the Cardiomyopathy registry’ during:
•    The session ‘ESC registries’, an EORP Special Session on Tuesday 1 September at 14:00 in the St James Park (The Hub)
2About EORP: EURObservational Research Programme (EORP) is the large ESC registry programme. EORP aims at providing a better understanding of medical practice in Europe through the collection of observational data and at evaluating the implementation of ESC guidelines.

Notes to editor

SOURCES OF FUNDING: At the time of the registry, the following companies were supporting the EURObservational Research programme: Abbott Vascular Int., Amgen, Bayer Pharma AG, Boehringer Ingelheim, Boston Scientific International, The Bristol Myers Squibb and Pfizer alliance, The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company, Menarini International Operations, Merck & Co., Novartis Pharma AG, SERVIER.
DISCLOSURES:
Philippe Charron reports travel expenses from the European Society of Cardiology; Aldo P. Maggioni reports Board membership fees from Novartis, Cardiorentis and Bayer; Michal Tendera reports personal fees from Bayer, Servier, Cardio-3 Biosciences, Stealth Biotherapeutics, grants and personal fees from Janssen-Cilag and grants from the Polish National Center for Research and Development.

ESC Press Office
For background information or assistance, please contact the ESC Press Office.
For independent comment on site or interviews, please contact the ESC spokesperson coordinator: +44 7785 467 947


About the European Society of Cardiology
The European Society of Cardiology (ESC) represents more than 90 000 cardiology professionals across Europe and worldwide. Its mission is to reduce the burden of cardiovascular disease in Europe.
 
About ESC Congress 2015
ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2015 takes place 29 August to 2 September at ExCel London in London, UK. Access the scientific programme. More information is available from the ESC Press Office at press@escardio.org.

To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.  

This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2015. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.